주식/NEWS & ISSUES

Novavax(NVAX) Current Approval Status

ZINOW 2021. 11. 16. 20:13
반응형

Current approval status of Novavax COVID-19 vaccine


[Summary]

NVAX Current Approval Status (@NOV 16, 2021)

Extracted from Novavax homepage


[News Realted to Submission & Approval]

  • AUG 5, 2021 : Submission to India, Indonesia and Philippines

https://ir.novavax.com/2021-08-05-Novavax-and-Serum-Institute-of-India-Announce-Submission-to-Regulatory-Agencies-in-India,-Indonesia,-Philippines-for-Emergency-Use-Authorization-of-Novavax-Recombinant-Nanoparticle-COVID-19-Vaccine

 

Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency U

- Novavax and Serum Institute of India file regulatory submissions to the Drugs Controller General of India and to regulatory agencies in Indonesia and Philippines for Novavax' recombinant...

ir.novavax.com

 

  • SEP 23, 2021 : Submission to WHO

https://ir.novavax.com/2021-09-23-Novavax-and-Serum-Institute-of-India-Announce-Submission-to-World-Health-Organization-for-Emergency-Use-Listing-of-Novavax-COVID-19-Vaccine

 

Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVI

Novavax and Serum Institute of India file regulatory submission for World Health Organization Emergency Use Listing of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine...

ir.novavax.com

 

  • OCT 27, 2021 : Submission to UK

https://ir.novavax.com/2021-10-27-Novavax-Files-for-Authorization-of-its-COVID-19-Vaccine-in-the-United-Kingdom

 

Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom

Filing marks first protein-based COVID-19 vaccine submitted to MHRA for authorization All modules required for regulatory review, including CMC data, are now complete Submission based on Phase 3...

ir.novavax.com

 

  • OCT 29, 2021 : Submission to Australia

https://ir.novavax.com/2021-10-29-Novavax-Files-for-Provisional-Approval-of-its-COVID-19-Vaccine-in-Australia

 

Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion of its...

ir.novavax.com

 

  • NOV 1, 2021 : Submission to Canada and EU

https://ir.novavax.com/2021-11-01-Novavax-Files-for-COVID-19-Vaccine-Authorization-with-Health-Canada-and-Completes-Submission-for-Rolling-Review-to-European-Medicines-Agency

 

Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medi

Health Canada filing marks first protein-based COVID-19 vaccine submitted for authorization to regulatory authorities in Canada Submission of all modules required for regulatory review, including...

ir.novavax.com

 

  • NOV 01, 2021 : Approval of Indonesia

https://ir.novavax.com/2021-11-01-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-Indonesia

 

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd....

ir.novavax.com

 

  • NOV 03, 2021 : Submission to New Zealand

https://ir.novavax.com/2021-11-03-Novavax-Files-COVID-19-Vaccine-for-Provisional-Approval-in-New-Zealand

 

Novavax Files COVID-19 Vaccine for Provisional Approval in New Zealand

- Submission to New Zealand's Medsafe marks the first protein-based COVID-19 vaccine submitted for authorization to regulatory authorities in New Zealand - All modules required for regulatory...

ir.novavax.com

 

  • NOV 15, 2021 : Submission to Korea

https://ir.novavax.com/2021-11-15-Novavax-Announces-Submission-of-Biologics-License-Application-in-South-Korea-for-Approval-of-NVX-CoV2373

 

Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373

SK bioscience submits application for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for BLA, to South Korea's MFDS GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc....

ir.novavax.com

 


 

반응형